What is Esperion Therapeutics's revenue?

Esperion Therapeutics (ESPR) generated $418.2M in revenue over the trailing twelve months, up 61.1% year over year.

Is Esperion Therapeutics profitable?

Esperion Therapeutics is not currently profitable: it reported a net loss of $109.7M over the trailing twelve months, a -34.8% net margin.

What is Esperion Therapeutics's earnings per share?

Esperion Therapeutics's diluted EPS over the trailing twelve months is $-0.53.

Where does Esperion Therapeutics's income statement data come from?

Every line is extracted from Esperion Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Esperion Therapeutics ESPR Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Total revenue	$418.24M+3.7%	$403.14M+32.7%	$303.8M+13.3%	$268.13M+3.3%	$259.57M-21.9%
Research and development	$44.28M-7.5%	$47.85M+6.6%	$44.9M+9.1%	$41.17M-9.3%	$45.39M-1.8%
Selling, general and administrative	$165.91M+0.1%	$165.79M+2.8%	$161.28M+1.2%	$159.41M-2.8%	$164.08M+0.6%
Other operating expenses	$342.46M-0.1%	$342.86M+2.9%	$333.18M+9.8%	$303.57M+1.3%	$299.54M+7.8%
Total operating expenses	$342.46M-0.1%	$342.86M+2.9%	$333.18M+9.8%	$303.57M+1.3%	$299.54M+7.8%
Total costs & expenses	——	$129.22M+13.3%	$114.07M+15.3%	$98.91M+18.1%	$83.76M+22.1%
Operating income	$75.79M+25.7%	$60.27M+341%	-$24.96M+19.6%	-$31.03M+12.7%	-$35.54M-160%
Operating margin	18.1%+3.2pp	15%+23.2pp	-8.2%+3.4pp	-11.6%+2.1pp	-13.7%-31.4pp
Interest expense	$84.97M+0.4%	$84.6M+7.9%	$78.39M+9.8%	$71.42M+10.5%	$64.66M+9.1%
Other income (expense), net	$3.6M+3.2%	$3.49M-3.6%	$3.62M-20.0%	$4.53M-28.3%	$6.32M-21.3%
Income before income taxes	——	-$20.84M+27.0%	-$28.57M+21.3%	-$36.29M+17.6%	-$44.02M+14.9%
Income tax expense	——	$1.84M+33.3%	$1.38M+50.0%	$920.5K+100%	$460.25K—
Net income	——	——	-$105.83M-1.7%	-$104.02M+32.1%	-$153.22M-196%
Diluted earnings per share	——	——	-$0.54-1.9%	-$0.53+33.7%	-$0.80-220%
Basic earnings per share	——	——	-$0.54-1.9%	-$0.53+33.7%	-$0.80-248%
Weighted-average shares, diluted	857.5M+6.9%	802.3M+2.6%	781.6M+0.7%	775.8M+1.1%	767M+0.9%
Weighted-average shares, basic	857.5M+6.9%	802.3M+2.6%	781.6M+0.7%	775.8M+1.1%	767M+3.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	——	——	-$105.83M-1.7%	-$104.02M+32.1%	-$153.22M-196%
Other income, net (Note 6)	$3.6M+3.2%	$3.49M-3.6%	$3.62M-20.0%	$4.53M-28.3%	$6.32M-21.3%
Research and development expense	$44.28M-7.5%	$47.85M+6.6%	$44.9M+9.1%	$41.17M-9.3%	$45.39M-1.8%
Revenue From Contract With Customer Excluding Assessed Tax	$418.24M+3.7%	$403.14M+32.7%	$303.8M+13.3%	$268.13M+3.3%	$259.57M-21.9%
EBIT	$75.79M+25.7%	$60.27M+341%	-$24.96M+19.6%	-$31.03M+12.7%	-$35.54M-160%
EBITDA	$75.89M+25.7%	$60.38M+343%	-$24.85M+19.6%	-$30.92M+12.8%	-$35.45M-160%
EBITDA	$75.89M+25.7%	$60.38M+343%	-$24.85M+19.6%	-$30.92M+12.8%	-$35.45M-160%
EBITDA margin	18.1%+3.2pp	15%+23.2pp	-8.2%+3.4pp	-11.5%+2.1pp	-13.7%-31.4pp
EBIT	$75.79M+25.7%	$60.27M+341%	-$24.96M+19.6%	-$31.03M+12.7%	-$35.54M-160%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Esperion Therapeutics.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Esperion Therapeutics's revenue?: Esperion Therapeutics (ESPR) generated $418.2M in revenue over the trailing twelve months, up 61.1% year over year.
Is Esperion Therapeutics profitable?: Esperion Therapeutics is not currently profitable: it reported a net loss of $109.7M over the trailing twelve months, a -34.8% net margin.
What is Esperion Therapeutics's earnings per share?: Esperion Therapeutics's diluted EPS over the trailing twelve months is $-0.53.
Where does Esperion Therapeutics's income statement data come from?: Every line is extracted from Esperion Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.